A study published in Cancer Epidemiology, Biomarkers & Prevention found that breast cancer survivors gained an average of 3.81 pounds more than cancer-free women within five years of diagnosis and treatment. Chemotherapy treatment was also significantly associated with weight gain, particularly among those treated recently.
Researchers found that high levels of ALK1 protein in breast tumor vasculature correlate with increased risk of metastatic disease. An investigational drug targeting ALK1 prevented disease spread in preclinical studies, offering a potential new therapeutic approach for treating metastatic breast cancer.
Researchers found that patients positive for HPV16 E1, E4-7, L1, L2, and E2 antibodies had better overall and progression-free survival compared to those negative. This suggests that these antibodies may be used to identify patients at risk of oropharyngeal cancer recurrence and death.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that lung cancer patients with comorbidities such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death. These patients also experienced poorer survival rates at each stage of the disease.
The American Association for Cancer Research (AACR) has partnered with Bayer HealthCare to expand its Basic Cancer Research Fellowship Program. The partnership aims to support young scientists conducting basic cancer research, addressing the current funding crisis in biomedical research.
A phase I study found that Sym004, a double-targeting EGFR antibody, provides better outcomes than current anti-EGFR therapies in patients with resistant colorectal cancer. The treatment resulted in significant antitumor activity and improved disease-control rates.
A study published in Cancer Epidemiology & Biomarkers & Prevention found that prolonged statin use after a lung cancer diagnosis was associated with a reduced risk of dying from lung cancer. Patients who used at least 12 prescriptions of statins had a 19% lower risk of lung cancer-specific deaths.
Margaret Foti, AACR CEO, will receive the Children's Champion Award for her outstanding pediatric cancer advocacy efforts. The award recognizes her leadership in advancing research and treatment for children with cancer.
David Baltimore is being recognized for his groundbreaking discoveries in immunology, virology, and cancer research. He will present a lecture on microRNAs, leukemia, and hematopoietic stem cells homeostasis at the AACR Annual Meeting 2015.
Dr. Carl June is being recognized for his contributions to cancer immunology, particularly his development of chimeric antigen receptor (CAR) T-cell therapy. His work has enhanced the promise of cancer immunotherapy and led to significant breakthroughs in treating leukemia.
A research team led by Charles Sawyers and Howard Scher discovered novel antiandrogen enzalutamide, which extended survival among patients with metastatic castration-resistant prostate cancer. The AACR Team Science Award recognizes the team's innovative work in advancing cancer research.
Dr. Mario Capecchi has made significant contributions to cancer research through his development of gene targeting technology, revolutionizing the study of cancer genes and mechanisms of cancer development. He will be presented with the AACR Award for Lifetime Achievement in Cancer Research at the 2015 Annual Meeting.
Dr. Coffey will receive the award for his pioneering work on prostate cancer, nuclear matrix, and mentoring of young researchers. He is also recognized for his outstanding leadership skills and advocacy for sustained funding for cancer research.
James P. Allison is being acknowledged for his discovery that blocking CTLA-4 signaling improves antitumor immune responses, leading to the development of ipilimumab, a cancer immunotherapeutic. His research has transformed the lives of patients with melanoma and offers hope for other forms of cancer.
The American Association for Cancer Research (AACR) and Pancreatic Cancer Action Network have awarded $27 million in research grants to support innovative projects targeting pancreatic cancer. The grants aim to improve treatment and diagnosis of the deadly disease, which has the lowest survival rate among major cancers.
Dr. Owen Witte, a pioneer in human leukemias and immune disorders, received the AACR G.H.A. Clowes Memorial Award for his groundbreaking work on tyrosine kinases as drug targets. His discoveries have led to multiple approved targeted therapies, transforming patient outcomes.
The study found that an estimated 388,501 childhood cancer survivors exist in the US, with 70% having a mild or moderate chronic condition and 32% having severe or disabling chronic conditions. Neurocognitive dysfunction affects about 35% of young adult survivors.
Dr. Lewis C. Cantley is being recognized for his groundbreaking work in discovering the phosphoinositide 3-kinase (PI3K) enzyme and elucidating its role in cancer development. His research has led to the development of personalized cancer therapies targeting the PI3K signaling pathway.
Low is being recognized for his pioneering development of low molecular weight ligands to deliver attached therapeutic and imaging agents selectively into pathologic cells such as cancer cells. This targeted therapeutic approach improves potency and reduces toxicity.
Dr. William Hahn receives the 39th annual AACR-Rosenthal Memorial Award for his seminal work on cancer initiation, maintenance, and progression. His research provides a foundation for novel therapeutic approaches now being tested in the clinic.
Dr. Elizabeth Jaffee receives the AACR-Joseph H. Burchenal Award for her pioneering contributions to immunotherapies for breast and pancreatic cancers, leading to improved treatments and patient outcomes. Her work also focuses on establishing biomarkers of tumor microenvironment reprogramming.
Dr. Sara A. Courtneidge is being recognized by the American Association for Cancer Research (AACR) for her groundbreaking research on Src-family kinases and their role in cancer development. Her work has also focused on promoting women in science, leadership, and mentorship.
Dr. Vakoc's work reveals an essential connection between epigenetic regulation and oncogenesis, leading to potential new therapeutic approaches for leukemias and other cancers. He will present his lecture at the AACR Annual Meeting 2015.
Dr. Mitchell Gail recognized for pioneering statistical work in cancer research, including breast cancer risk prediction models. His research has led to the development of widely used tools like the NCI's Breast Cancer Risk Assessment Tool.
Dr. Lucile Adams-Campbell is recognized for her scientific work in cancer epidemiology and health disparities, as well as her dedication to mentoring minority researchers. She will receive the AACR-MICR Jane Cooke Wright Lectureship at the AACR Annual Meeting 2015.
A genetically engineered immunotoxin called DT2219 has shown safety and clinical effectiveness in a phase I trial for patients with relapsed/refractory B-cell malignancies. Two patients achieved durable objective responses, highlighting the potential of this new treatment approach.
A retrospective cohort study found that metformin use was associated with a decreased risk of lung cancer in diabetic patients who had never smoked. Nonsmokers taking metformin for five years or longer showed a 52% reduction in lung cancer risk, but this finding was not statistically significant.
A study has identified a new signaling pathway that generates slowly proliferating, chemo-resistant cancer cells. This pathway may offer new avenues for reducing tumor heterogeneity and improving treatment outcomes.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that men with high cholesterol and triglyceride levels after prostate cancer surgery had a higher risk of disease recurrence. Normalizing lipid levels may reduce this risk.
A phase Ib clinical trial found that olaparib tablets were safe and effective in heavily pretreated ovarian cancer patients, particularly those with BRCA mutations. The treatment regimen provided a response rate of 66 percent and no grade 4 toxicities, making it a promising option for improving cure rates and quality of life.
A population-based case-control study found no evidence that wearing a bra increases the risk of breast cancer among postmenopausal women. The study analyzed bra-wearing habits in relation to breast cancer risk using a rigorous epidemiological study design, providing reassurance to women about their bra-wearing habits.
Regular use of aspirin or other NSAIDs has been found to reduce the risk of hormone-related breast cancer recurrence by half in overweight and obese women. The study suggests that limiting inflammatory signaling may be an effective approach to altering the cancer-promoting effects of obesity.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that postmenopausal women who exercised at least four hours of walking per week had a 10% decreased risk of invasive breast cancer. The benefits of regular physical activity were rapid and short-lived, disappearing if exercise stopped.
Researchers found that gut microbiome analysis successfully distinguished healthy individuals from those with precancerous adenomatous polyps and invasive colorectal cancer. The composition of the gut microbiome was different for each group, leading to improved prediction of colorectal cancer presence.
A new study suggests that consuming resistant starch alongside red meat can lower the risk of colorectal cancer. The study found that butyrated resistant starch reduced levels of certain genetic molecules associated with cell proliferation and increased risk of cancer.
A recent study published in Cancer Research found that women who recently used birth control pills containing high-dose estrogen had an increased risk for breast cancer. The study suggests that this risk may vary by oral contraceptive formulation, and it is essential to consider the established health benefits of oral contraceptive use...
Research suggests that dim light exposure at night can suppress melatonin production in rats with human breast tumors, making them resistant to the breast cancer drug tamoxifen. However, giving these rats a melatonin supplement during the night restored their tumor sensitivity to the drug.
A new approach identified two mutated tumor targets, KIF2C and POLA2, that play important roles in cell proliferation and may stimulate immune responses. This study provides a technical solution to identify mutated tumor targets for adoptive T-cell therapy, which has shown promise in treating metastatic melanoma.
A study published by the American Association for Cancer Research found that low-dose aspirin significantly reduces the risk of pancreatic cancer. The longer a person takes low-dose aspirin, the lower their risk of developing pancreatic cancer, with some evidence suggesting a greater reduction in risk over time.
A new imaging technique combining four approaches can distinguish between malignant and benign breast tumors with high accuracy, potentially avoiding unnecessary biopsies. The multiparameter PET-MRI method showed a 96% success rate in distinguishing malignant from benign tumors.
A study found that childhood cancer survivors were hospitalized more often and for longer durations than the general population, with conditions like blood disorders and infections leading to hospitalizations. The study highlights the need for regular cancer-focused healthcare to identify health problems throughout their lives.
A study found that young adults who smoked water pipes in hookah bars had significantly elevated levels of nicotine, cotinine, and tobacco-related cancer-causing agents in their urine. This may increase their risk for cancer and other chronic diseases.
A study found that vitamin D deficiency was associated with aggressive prostate cancer diagnosis and tumor progression in both European-American and African-American men. Lower levels of 25-hydroxyvitamin D (25-OH D) were linked to higher odds of having aggressive prostate cancer and faster disease progression.
A new computational model simulates bone metastasis of prostate cancer and accurately predicts the impact of potential therapies on cancer cells and normal cells of the bone. The model was validated by comparing its predictions with tumor growth rates in mice, and identified critical players and events in the process of bone metastasis.
A study found that chronic inflammation in benign prostate tissue was associated with high-grade prostate cancer. Men with at least one biopsy core showing inflammation had a 1.78 times higher odds of having prostate cancer and a 2.24 times higher odds of having aggressive disease.
The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team aims to develop new therapies using patients' own immune cells to treat pancreatic cancer. The team, led by experts in various institutions, will focus on understanding the tumor microenvironment and developing therapeutic agents to eliminate barriers to treatment.
A research team led by Ellis L. Reinherz and Robert I. Haddad will focus on developing new vaccines and immunotherapeutic approaches to improve outcomes for patients with HPV-driven cancers who have relapsed after initial therapy. The grant aims to provide a novel approach to treating this population.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that women who took clomiphene citrate or gonadotropins for fertility treatment did not have an increased risk of breast cancer over 30 years. However, a small number of women had a higher risk after multiple cycles of these medications.
A phase I trial found a complete response for 14 months to everolimus and pazopanib in a patient with advanced bladder cancer and rare mTOR genetic mutations. Genomic profiling revealed two alterations that activated the mTOR-mediated cell signaling pathway, rendering the cancer sensitive to the mTOR inhibitor.
Dr. Elaine Fuchs received the Pezcoller Foundation-AACR International Award for her seminal work on mammalian skin, skin stem cells, and related diseases. Her research has had a profound impact on cancer research and other disciplines, including genetics and dermatology.